That is exactly what may have happened. Also, they

That is exactly what may have happened. Also, they simply don't need a BP or Diagnostics company yet. FDA approval is many months out. The best choice in the market they are about to enter is an ICON like company. They can now generate revenue and be in a better position to negotiate with a commercial partner. But, who knows, once LP002 comes out and we approach CLIA launch maybe a commercial partner will belly up to the bar. They may not even partner at that point. They might just sell Lympro and NuroPro. Maybe that is the plan. 'PARTNER' with ICON, generate revenue/value, then sell - not partner. Why partner with a BP now when they will all be clamoring for it later. If we signed a classic partner now we would likely have to give them first right to buy if another offer came in. Who wants that.

I could forsee having a MANF or Eltoprazine commercial partner before a Lympro commercial partner. Very possible. MANF is about to have 2 opthamalogic orphans very soon and that will attract major attention.